177Lu-DOTATATE

You have access
Safety of Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease
Shahad Alsadik, Gopinath Gnanasegaran, Luohai Chen, Dalvinder Mandair, Christos Toumpanakis, Martyn Caplin and Shaunak Navalkissoor

Journal of Nuclear Medicine October 1, 2022, 63 (10) 1503-1508; DOI: https://doi.org/10.2967/jnumed.121.263056
Open Access
Modeling Early Radiation DNA Damage Occurring During ¹⁷⁷Lu-DOTATATE Radionuclide Therapy
Giulia Tamborino, Yann Perrot, Marijke De Saint-Hubert, Lara Struelens, Julie Nonnekens, Marion De Jong, Mark W. Konijnenberg and Carmen Villagrasa

Journal of Nuclear Medicine May 1, 2022, 63 (5) 761-769; DOI: https://doi.org/10.2967/jnumed.121.262610
You have access
Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with ¹⁷⁷Lu-DOTATATE
Daniel Roth, Johan Gustafsson, Carl Fredrik Warfvinge, Anna Sundlöv, Anna Åkesson, Jan Tennvall and Katarina Sjögreen Gleisner

Journal of Nuclear Medicine March 1, 2022, 63 (3) 399-405; DOI: https://doi.org/10.2967/jnumed.121.262069
Open Access
Dosimetric Evaluation of the Effect of Receptor Heterogeneity on the Therapeutic Efficacy of Peptide Receptor Radionuclide Therapy: Correlation with DNA Damage Induction and In Vivo Survival
Giulia Tamborino, Julie Nonnekens, Marijke De Saint-Hubert, Lara Struelens, Danny Feijtel, Marion de Jong and Mark W. Konijnenberg

Journal of Nuclear Medicine January 1, 2022, 63 (1) 100-107; DOI: https://doi.org/10.2967/jnumed.121.262122
You have access
A Novel Time–Activity Information-Sharing Approach Using Nonlinear Mixed Models for Patient-Specific Dosimetry with Reduced Imaging Time Points: Application in SPECT/CT After ¹⁷⁷Lu-DOTATATE
Theresa P. Devasia, Yuni K. Dewaraja, Kirk A. Frey, Ka Kit Wong and Matthew J. Schipper

Journal of Nuclear Medicine August 1, 2021, 62 (8) 1118-1125; DOI: https://doi.org/10.2967/jnumed.120.256255
You have access
A Rapid and Safe Infusion Protocol for ¹⁷⁷Lu Peptide Receptor Radionuclide Therapy
Sander C. Ebbers, Maarten W. Barentsz, Bart de Keizer, Gerard C. Krijger, Marnix G.E.H. Lam and Arthur J.A.T. Braat

Journal of Nuclear Medicine June 1, 2021, 62 (6) 816-822; DOI: https://doi.org/10.2967/jnumed.120.252494
You have access
Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy
Jonathan R. Strosberg, Taymeyah Al-Toubah, Eleonora Pellè, Johnna Smith, Mintallah Haider, Tai Hutchinson, Jason B. Fleming and Ghassan El-Haddad

Journal of Nuclear Medicine January 1, 2021, 62 (1) 69-72; DOI: https://doi.org/10.2967/jnumed.120.242875
You have access
Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in ¹⁷⁷Lu-DOTATATE Therapy: An In Silico Analysis for Standard and Optimized Treatment
Luis David Jiménez-Franco, Gerhard Glatting, Vikas Prasad, Wolfgang A. Weber, Ambros J. Beer and Peter Kletting

Journal of Nuclear Medicine January 1, 2021, 62 (1) 92-98; DOI: https://doi.org/10.2967/jnumed.120.245068
You have access
In Vivo Instability of ¹⁷⁷Lu-DOTATATE During Peptide Receptor Radionuclide Therapy
Mark Lubberink, Helena Wilking, Amalia Öst, Ezgi Ilan, Mattias Sandström, Camilla Andersson, Katarzyna Fröss-Baron, Irina Velikyan and Anders Sundin

Journal of Nuclear Medicine September 1, 2020, 61 (9) 1337-1340; DOI: https://doi.org/10.2967/jnumed.119.237818
Open Access
Imaging DNA Damage Repair In Vivo After ¹⁷⁷Lu-DOTATATE Therapy
Edward O’Neill, Veerle Kersemans, P. Danny Allen, Samantha Y.A. Terry, Julia Baguña Torres, Michael Mosley, Sean Smart, Boon Quan Lee, Nadia Falzone, Katherine A. Vallis, Mark W. Konijnenberg, Marion de Jong, Julie Nonnekens and Bart Cornelissen

Journal of Nuclear Medicine May 1, 2020, 61 (5) 743-750; DOI: https://doi.org/10.2967/jnumed.119.232934

Main menu

User menu

Search

177Lu-DOTATATE

Pages